New drug interaction study for opioid treatments launches

NCT ID NCT07314346

Recruiting now Knowledge-focused Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This early-stage study looks at how a new antiviral drug combination (BEM/RZR) affects the levels of two common opioid addiction treatments—buprenorphine/naloxone and methadone—in healthy adults. Researchers will give participants their usual opioid therapy plus the antiviral drug and measure drug concentrations in the blood. The goal is to see if the antiviral changes how these opioids work in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bemnifosbuvir/Ruzasvir (BEM/RZR) combined with buprenorphine/naloxone or methadone
What this could lead to: If successful, this study could help doctors understand how to safely combine a new antiviral drug with common opioid addiction treatments.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only checks drug levels, not whether the combination is safe or effective for treating disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER STUDY

Contacts and locations

Locations

Atea Study Site
RECRUITING

Hollywood, Florida, 33019, United States
Atea Study Site
RECRUITING

Overland Park, Kansas, 66212, United States
Atea Study Site
RECRUITING

Marlton, New Jersey, 08053, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.